Denver, CO, August 16, 2008 --(PR.com
)-- LegalView, the most comprehensive legal resource available on the Web, recounted the results of an Italian study to its mesothelioma information
blog readers. The study attempted to increase the survival rate of elderly pleural mesothelioma patients by combining two medications: Alimta (pemtrexed) and Paraplatin (carboplatin). The results of the study were released in a June issue of the British Journal of Cancer and the conclusions detailed the highly-effective treatments, which increased the survival rate among pleural mesothelioma patients 65 years of age or older.
Mesothelioma is an incurable cancer that is often attributed to the inhalation of asbestos fibers and dust containing tremolite. Asbestos is a known carcinogen, according to the Environmental Protection Agency (EPA), which is responsible for regulating the cleanup of the hazardous material. Asbestos was often prized for its ability to remain fire-resistant, while being produced cheaply, and served as a key ingredient in many products including insulation that was implemented into homes, apartment complexes, universities, schools, business offices and hospitals around the country. Individuals who suffer from mesothelioma cancer are advised to speak with a knowledgeable mesothelioma attorney in order to better educate themselves on the possibility for developing a mesothelioma lawsuit. Due to the extremely costly medical bills associated with increasing survival rate among mesothelioma cancer victims, developing litigation may result in monetary compensation to assist with those medical bills.
LegalView not only offers resources on the most recent mesothelioma news and clinical trials, but also offers information on a variety of other legal issues afflicting millions of Americans. Most recently, LegalView updated several of its pharmaceutical drug information portals with news on updates and recalls; some of the portals include Viapro, Ketek and the Zimmer Durom cup.
The development of the Viapro information portal occurred after the U.S. Food and Drug Administration (FDA) issued a press release on the recall of the drug because of contamination of a harmful chemical known as thiomethisosildenafil. The male sexual-enhancement prescription drug, manufactured by EG Labs, is used to treat erectile dysfunction (ED). The undeclared ingredient may be harmful to patients especially when interacting with nitrates found in other prescription drugs. The Viapro recall occurred because the drug may cause dangerously low levels of blood pressure among patients also taking nitroglycerin for diabetes, high blood pressure, high cholesterol or heart disease.
Ketek, which is an antibiotic used to treat upper respiratory infections such as pneumonia, bronchitis and sinusitis, had its warning labels increased recently due to the threat of liver disease among patients consuming the drug. To learn more about the Ketek side effects, visit http://ketek.legalview.com/.
Also among the recently updated information portals is that of the Zimmer Durom cup. Zimmer Holdings has ceased production of its Durom cup because of complaints that the hip socket was failing among many patients. Although the company has ceased production of the hip socket, pending internal investigations into the potential failure, the hip socket has already been used in over 12,000 hip replacement procedures since its introduction to the market in 2006. Patients who may be at risk for the Durom cup failure should seek medical attention immediately to ensure no further damage occurs.
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.